Registration or market approval of a drug by a country’s drug regulatory agency grants permission for a product from a specific manufacturer to be marketed in that country for the medical indications for which the application is made. The drug is then added to the country’s list of registered medicines. Since oxytocin and magnesium sulfate are included in national policies for maternal health in most countries, it is expected that these medicines would be registered in most countries. Evidence of this can be found in the USAID/MCHIP report, which identified that magnesium sulfate is registered in all countries (31) surveyed.
